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Antibodies were made to a thirteen amino acid synthetic peptide corresponding to the C-terminal portion of the glutamate (glu) receptor, GluR-A. 
The immunoprecipitation of kainic acid (KA) and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) binding sites by the anti-peptide 
antibodies was studied using a detergent-solubilized preparation of rat brain membranes. Under these conditions a subpopulation of AMPA binding 
sites was recognized by the antibodies, but no KA binding sites were recognized. Scatchard analysis of this subpopulation of AMPA binding sites 
yields a curvilinear plot which fits a two-site model with dissociation constants of 4.6 and 323 nM. These studies how that the glu receptor complex, 
GluR-A, binds AMPA but not KA and suggest hat (i) the binding sites for these two ligands reside on different proteins, and (ii) the KA receptor 
identified physiologically is not equivalent o the KA binding sites identified with 3H-labelled KA. 
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1. INTRODUCTION 
Excitatory amino acids (EAA) are major 
neurotransmitters in the mammalian brain and have 
been implicated in several critical neurological events 
including neurotoxicity, neurodegenerative disorders 
and learning and memory [ 11. EAA receptors have been 
characterized with respect to their physiological 
responses to agonists and antagonists and their binding 
properties using radiolabeled ligands. Both approaches 
have identified three major populations of receptors: 
the N-methyl-D-aspartate (NMDA), quisqualate or IX- 
amino-3-hydroxy-5-methyl-4 isoxazolepropionic acid 
(AMPA), and kainic acid (KA) receptors [1,2]. While 
both binding and physiological studies clearly differen- 
tiate between NMDA and non-NMDA receptors, KA 
and AMPA receptors are not well defined. Several 
studies have suggested that the physiologically active 
sites for these two agonists may be the same or 
associated with the same receptor complex [3-71. Both 
KA and AMPA bind to mammalian brain with high af- 
finity [2,8-111 and their binding sites have different 
distributions [ 12,131. However, the relationship be- 
tween the high affinity binding sites for KA and AMPA 
and the physiologically active receptors of these 
agonists has not been conclusively demonstrated. A 
glutamate (glu) receptor from rat brain has been cloned 
through functional expression using the Xenopus 
oocyte for expression of mRNA [ 141. The physiological 
properties of the oocyte-expressed receptor suggest hat 
it is a KA subtype of excitatory amino acid receptor. 
However, this receptor (GluR-A) and 3 related recep- 
tors have recently been shown to bind AMPA when ex- 
pressed in cultured mammalian cells [15]. To further 
characterize this receptor, we have studied the binding 
properties of GluR-A in a detergent-solubilized 
preparation from rat membranes using antibodies to a 
C-terminal peptide of the protein. 
2. MATERIALS AND METHODS 
KA and AMPA binding sites were solubilized from rat brain mem- 
branes with Triton X-100 as previously described [S], except hat the 
temperature of the solubilization step was 4°C instead of 37°C. Under 
these conditions both solubilized KA and AMPA binding sites were 
obtained. The solubilized preparation was dialyzed extensively in 
THCl buffer (50 mM Tris-HCI, pH 7.0,10% (w/v) glycerol and 0.1% 
(w/v) Triton X-100). All subsequent experiments with the solubilized 
binding sites were done in this buffer. [‘HIAMPA binding was 
routinely done at 10 nM in the presence of 0.1 M KSCN as described 
[8]. For Scatchard analysis of [3H]AMPA binding, concentrations 
ranging from 5 to 500 nM were used. Data were analyzed using the 
Ligand program, a computerized non-linear curve-fitting program 
[16]. In competition experiments the concentration of competing 
compound inhibiting 50% of the binding activity (ICso) was determin- 
ed by logit-log analysis [17]. [3H]KA binding was done at 5 and 50 nM 
as described [18]. 
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A synthetic peptide, SHSSGMPLGATGL (single letter code), 
which corresponds to the C-terminal of GluR-A (initially called GluR- 
Kl [14]) was prepared commercially. Of the four glu receptors whose 
sequence has been determined, this sequence is specific to GluR-A 
[15,19]. However, this sequence overlaps to a limited extent with the 
C-terminal sequence of GluR-D, RQSSGLAVIASDLP. Therefore, 
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Fig. 1. Immunoblot analyses of SDS gels of rat brain tissues using 
anti-peptide antibodies. A, hippocampus; B, cerebellum; C, cortex; 
D, brain-stem. Twenty-five micrograms of protein was applied to 
each lane. Arrows show the positions of molecular weight standards 
@-galactosidase, h&= 116000; phosphory~ase b, lw,=97000; bovine 
serum albumin, M, = 67000; and ovalbumin, &f, = 44000. 
we cannot rule out the possibility that GluR-D is recognized by an- 
tibodies to the C-terminal peptide of GluR-A. The peptide was con- 
jugated to BSA with glutaraldehyde, and after dialysis, the conjugate 
was injected into New Zealand White rabbits for producing an- 
tibodies. Antibodies were attached to Protein A-agarose, and after 
thorough washing to remove serum components, columns of the im- 
mobilized antibody (100 pl bed volume) were used to determine an- 
tibody recognition of the solubilized AMPA and KA binding sites 
[20]. Aliquots of the solubilized preparation were applied to the col- 
umns and incubated at 4°C for 1.5 h. 13H]AMPA and [‘H]KA bind- 
ing were measured in the unbound fractions from columns contain- 
ing anti-peptide antibodies and compared to those prepared with pre- 
immune serum or normal rabbit serum. [3H]AMPA binding and 
[-‘H]KA binding were done on the same fractions. For im- 
munopurification of AMPA binding sites, antibodies were covalently 
attached to Protein A-agarose [Zl]. To a column containing 0.6 ml of 
resin, 10 ml of solubilized preparation was applied and incubated for 
1.5 h at 4OC. After extensive washing with buffer, bound antigen was 
eluted with 10 ml of 1 M KSCN. f’H]AMPA binding was carried out 
on this fraction after dialysis. 
SDS-PAGE was performed according to the method of Laemmli 
[22] using gradient gels of 4-20% polyacrylamide. After elec- 
trophoresis, transfer to nitrocellulose membranes was done as 
described by Towbin [23}. Membranes were treated with 4.5% instant 
powdered milk in Tris-buffered saline (TBS; 50 mM Tris, 150 mM 
NaCl, pH 7.4) containing 0.05% Tween-20, followed by incubation in 
antibody at a dilution of l/1000 in the same buffer. Detection was 
carried out using an alkaline phosphatase-conjugated second an- 
tibody. 
3. RESULTS 
Immunoblot analysis of SDS gels of rat brain using 
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the anti-peptide antibody shows a single band migrating 
with a MI = 115000 in the four brain areas analyzed 
(Fig. 1). The size of the immunoreactive protein is con- 
sistent with the data from the cDNA clone for GluR-A 
which encodes a protein with a calculated molecular 
mass of 99800 Da [15]. The slightly larger molecular 
mass we obtain may be due to glycosylation of the pro- 
tein since GluR-A contains 6 possible glycosylation sites 
[ 141. The relative amounts of immunorea~tive protein is 
also consistent with in situ hybridization studies and 
Northern blot analyses howing high concentrations of 
GluR-A mRNA in cortex, cerebellum and hippocam- 
pus, and relatively little in brain stem [14,15]. 
Immunoprecipitation studies were carried out on rat 
brain membranes solubilized in Triton X-100 under 
conditions which give soluble binding sites for both 
AMPA and KA [f&18]. This allows the binding proper- 
ties of both ligands to be directly compared on the same 
fractions. Solubilized preparations were passed through 
columns of anti-peptide antibody coupled to Protein A- 
agarose [20] and antibody binding was assessed by 
determining the reduction in [3H]AMPA or i3H]KA 
binding in the unretained fraction, relative to controls. 
Using this protocol we find that a subpopulation 
(27-30%) of AMPA binding sites is removed by the an- 
tibodies, while no KA binding activity is removed 
(Table I). Most studies have demonstrated two KA 
binding sites in mammalian brain, a high affinity site 
with a dissociation constant between l-8 nM and a low 
affinity site with a dissociation constant between 27-65 
nM [2]. Since it has been suggested that the high and 
low affinity sites may be on different proteins [3], 3H- 
KA binding was done at both 5 and 50 nM. Increasing 
the amount of antibody attached to the column did not 
increase the amount of AMPA binding activity remov- 
ed, confirming that only a subpopulation of AMPA 
binding sites is recognized by the antibody. Varying the 
amount of Protein A-agarose also did not change the 
amount of AMPA binding removed (unpublished 
observation). These findings show that the binding sites 
Table 1 
Immunoprecipitation of AMPA and KA binding sites with anti- 
peptide antibodies 
Volume of 
serum 
Per cent Binding Recovered 
AMPA KA 
5nM 50 nM 
100 pl 72.4 * 4.8 96.8 + 6.3 98.8 * 4.2 
250 pl 70.7 k 1.6 98.7 f 3.9 nd 
Data are presented as per cent of binding activity unretained by a col- 
umn of Protein A-agarose to which anti-peptide antibody, 100 pl or 
250 pl serum, was bound relative to that of a column containing pre- 
immune serum or normal rabbit serum (mean f SD; n = 5 for 100 pl 
and n = 3 for 250 al). AMPA and KA binding were measured in the 
unbound fraction from the same column. [‘H]AMPA binding was 
done at 10 nM in the presence of 0.1 M KSCN. nd, not determined. 
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Fig. 2. (a) Scatchard analysis of [‘H]AMPA binding to the fraction retained on Protein A-agarose to which anti-peptide antibody was bound. Data 
were analyzed using the LIGAND program [16] and found to fit a two-site model. Dissociation constants of 4.6 + 1.7 nM and 323 f 186 nM 
were obtained for the high and low affinity sites, respectively (mean k SEM of 3 determinations). Bound are expressed as fmol/assay and 
bound/free are expressed as fmol/assay/nM. (b) Inhibition profiles of quisqualate, glutamate, 6,7-dinitroquinoxaline-2,3-dione (DNQX) and KA 
for [‘H]AMPA binding to fraction retained on Protein A-agarose. [‘HIAMPA binding was done at 10 nM. ICss values (mean + SD of 3 
determinations) obtained for quisqualate, glutamate, DNQX and KA were 0.018 k 0.004, 0.40 k 0.09, 0.99 + 0.16 and 2.0 k 0.4 pM, 
respectively. Figure a and b each show the average of 3 determinations. 
for KA (both high and low affinity sites) and AMPA in 
rat brain are associated with different proteins. 
To characterize the subpopulation of AMPA binding 
sites recognized by the antibody, the anti-peptide an- 
tibody was covalently attached to the Protein A-agarose 
[21]. Antigen bound to the column was eluted with 1 M 
KSCN, and [3H]AMPA binding was carried out on this 
fraction after dialysis. A curvilinear Scatchard plot is 
obtained which fits a two-site model with dissociation 
constants of 4.6 and 323 nM (Fig. 2). With respect to 
the presence of two binding sites, these results are 
similar to those found measuring the total population 
of AMPA binding sites that are either membrane 
associated [8,9-l l] or detergent solubilized [8]. 
However, the values of the dissociation constants are 
somewhat lower than those obtained for the total 
solubilized rat brain preparation (11.9 and 597 nM) [8]. 
Quisqualate, L-glutamate, 6,7-dinitroquinoxaline-2,3- 
dione (DNQX) and KA inhibited AMPA binding to the 
antibody-purified preparation (Fig. 2) at concentrations 
similar to those that inhibit binding to the total popula- 
tion of AMPA binding sites. Specific KA binding was 
also measured in the antibody-purified preparation and 
could not be detected at concentrations up to 1.5 PM 
(unpublished observation) suggesting that a lower af- 
finity binding site, such as that found in chick brain 
(Kd = 255 nM) [24], is also not present. 
4. DISCUSSION 
Our finding that antibodies to the C-terminal of the 
glu receptor subunit, GluR-A, recognize AMPA bind- 
ing sites, but not KA binding sites, has three interpreta- 
tions. (i) GluR-A is an AMPA binding protein which 
does not bind KA. (ii) GluR-A is subunit of a receptor 
complex which also contains an AMPA binding subunit 
and the entire complex is adsorbed by antibodies to 
GluR-A. If this is the case, the lack of KA binding to the 
complex remains unexplained. (iii) A significant por- 
tion of the C-terminal amino acid sequence of GluR-A 
used to produce the antibody is found both in GluR-A 
and in a distinct AMPA binding protein, but the an- 
tibody cannot bind GluR-A due to modifications of the 
C-terminal portion of the receptor. We consider the 
most likely interpretation to be that the KA receptor, 
GluR-A, is an AMPA binding protein which does not 
bind KA under the standard conditions used to measure 
its binding to mammalian brain. This is supported by 
the recent finding that, when expressed in mammalian 
cultured cells, GluR-A and related receptors expressed 
AMPA binding sites and not KA binding sites [ 151. 
Results using the transfected cells showed only a single 
class of binding sites with a dissociation constant of 12 
nM which is similar to that of the high affinity site (4.6 
nM) we observed for the antibody-purified receptor. 
However, a low affinity site, which we found for the 
antibody-purified receptor and which has been reported 
in many AMPA binding studies using mammalian brain 
membranes, is not present in the transfected cells. 
There are a number of explanations for this difference 
including the possibility that GluR-A undergoes dif- 
ferent posttranslational processing in neurons and 
cultured cells. 
The present results imply that the KA receptor and 
KA binding sites are distinct proteins in mammalian 
brain, as has been suggested by other studies. The 
strongest previous evidence supporting this contention 
is that rat brain KA receptors expressed in Xenopus 
oocytes show potencies of agonists for KA receptors 
that are lOOO-fold lower than those predicted from 
binding data, and the relative order of potencies of 
agonists applied to oocytes differs from that of binding 
149 
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studies [25]. If KA receptors and KA binding sites are 
distinct, the question as to the nature and function of 
KA binding sites in mammalian brain remains. These 
sites are of low abundance compared to AMPA binding 
sites and may represent a minor population of ex- 
citatory amino acid receptors. Recently cDNA clones 
for KA binding proteins from chick [26] and frog [27] 
brain have been isolated. These proteins bind KA, with 
the frog protein being pharmacologically in- 
distinguishable from that of mammalian brain, but they 
have not been shown to be functional ion channels. 
However, the KBP’s have several characteristics of a 
ligand-gated ion channel and have significant homology 
(35% amino acid identity) to the C-terminal half of 
GluR-A. A similar protein may be responsible for KA 
binding in mammalian brain, and the function of this 
protein remains to be determined. 
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